Activation of NF-κB is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The transcription factor NF-κB regulates expression of genes that are involved in inflammation, immune response, viral infection, cell survival, and division. However, the role of NF-κB in hypertrophic growth of terminally differentiated cardiomyocytes is unknown. Here we report that NF-κB activation is required for hypertrophic growth of cardiomyocytes. In cultured rat primary neonatal ventricular cardiomyocytes, the nuclear translocation of NF-κB and its transcriptional activity were stimulated by several hypertrophic agonists, including phenylephrine, endothelin-1, and angiotensin II. The activation of NF-κB was inhibited by expression of a “supersuppressor” IκBα mutant that is resistant to stimulation-induced degradation and a dominant negative IκB kinase (IKKβ) mutant that can no longer be activated by phosphorylation. Furthermore, treatment with phenylephrine induced IκBα degradation in an IKK-dependent manner, suggesting that NF-κB is a downstream target of the hypertrophic agonists. Importantly, expression of the supersuppressor IκBα mutant or the dominant negative IKKβ mutant blocked the hypertrophic agonist-induced expression of the embryonic gene atrial natriuretic factor and enlargement of cardiomyocytes. Conversely, overexpression of NF-κB itself induced atrial natriuretic factor expression and cardiomyocyte enlargement. These findings suggest that NF-κB plays a critical role in the hypertrophic growth of cardiomyocytes and may serve as a potential target for the intervention of heart disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses
Ghosh, S., May, M. J., & Kopp, E. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.225 · Cited by 5,182
THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 4,979
Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases
Barnes, P. J., & Karin, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704103361506 · Cited by 4,669
Baeuerle, P. A., & Baltimore, D. (1996) · Cell · doi:10.1016/s0092-8674(00)81318-5 · Cited by 3,001
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566
A cytokine-responsive IκB kinase that activates the transcription factor NF-κB
DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., & Karin, M. (1997) · Nature · doi:10.1038/41493 · Cited by 2,125
Self-citationIKK-1 and IKK-2: Cytokine-Activated IκB Kinases Essential for NF-κB Activation
Mercurio, F., Zhu, H., Murray, B. W., Shevchenko, A., Bennett, B. L., Li, J. W., Young, D. B., Barbosa, M., Mann, M., Manning, A., et al. (1997) · Science · doi:10.1126/science.278.5339.860 · Cited by 2,040
Self-citationZandi, E., Rothwarf, D. M., Delhase, M., Hayakawa, M., & Karin, M. (1997) · Cell · doi:10.1016/s0092-8674(00)80406-7 · Cited by 1,812
Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation.
Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van Antwerp, D., & Miyamoto, S. (1995) · Genes & Development · doi:10.1101/gad.9.22.2723 · Cited by 1,724
Control of IκB-α Proteolysis by Site-Specific, Signal-Induced Phosphorylation
Brown, K., Gerstberger, S., Carlson, L., Franzoso, G., & Siebenlist, U. (1995) · Science · doi:10.1126/science.7878466 · Cited by 1,434
Cited by
Cardiac Hypertrophy: The Good, the Bad, and the Ugly
Frey, N., & Olson, E. N. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142243 · Cited by 1,449
p38 MAP-Kinases pathway regulation, function and role in human diseases
Cuenda, A., & Rousseau, S. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.03.010 · Cited by 1,400
IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system
Sanada, S., Hakuno, D., Higgins, L. J., Schreiter, E. R., McKenzie, A. N. J., & Lee, R. T. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30634 · Cited by 1,044
Nuclear factor-?B: its role in health and disease
Kumar, A., Takada, Y., Boriek, A., & Aggarwal, B. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0555-y · Cited by 933
Dietary metabolism, the gut microbiome, and heart failure
Tang, W. H. W., Li, D. Y., & Hazen, S. L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0108-7 · Cited by 789
Multiple Facets of NF-κB in the Heart: To Be or Not to NF-κB
Gordon, J. W., Shaw, J. A., & Kirshenbaum, L. A. (2011) · Circulation Research · doi:10.1161/circresaha.110.226928 · Cited by 551
Morimoto, T., Sunagawa, Y., Kawamura, T., Takaya, T., Wada, H., Nagasawa, A., Komeda, M., Fujita, M., Shimatsu, A., Kita, T., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33160 · Cited by 423
Peroxisome Proliferator-Activated Receptors: Vascular and Cardiac Effects in Hypertension
Schiffrin, E. L., Amiri, F., Benkirane, K., Iglarz, M., & Diep, Q. N. (2003) · Hypertension · doi:10.1161/01.hyp.0000084370.74777.b6 · Cited by 369
Bodyak, N., Ayus, J. C., Achinger, S., Shivalingappa, V., Ke, Q., Chen, Y.-S., Rigor, D. L., Stillman, I., Tamez, H., Kroeger, P. E., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611202104 · Cited by 333
Braz, J. C., Bueno, O. F., Liang, Q., Wilkins, B. J., Dai, Y.-S., Parsons, S., Braunwart, J., Glascock, B. J., Klevitsky, R., Kimball, T. F., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17295 · Cited by 332
The Rac and Rho Hall of Fame: A Decade of Hypertrophic Signaling Hits
Brown, J. H., Del Re, D. P., & Sussman, M. A. (2006) · Circulation Research · doi:10.1161/01.res.0000216039.75913.9e · Cited by 323
Planavila, A., Iglesias, R., Giralt, M., & Villarroya, F. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq376 · Cited by 317
Role of the Renin-Angiotensin System in Vascular Diseases: Expanding the Field
Ruiz-Ortega, M., Lorenzo, O., Rupérez, M., Esteban, V., Suzuki, Y., Mezzano, S., Plaza, J. J., & Egido, J. (2001) · Hypertension · doi:10.1161/hy1201.100589 · Cited by 308
Jeong, W.-S., Kim, I.-W., Hu, R., & Kong, A.-N. T. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000022413.43212.cf · Cited by 264
β-Arrestin inhibits NF-κB activity by means of its interaction with the NF-κB inhibitor IκBα
Witherow, D. S., Garrison, T. R., Miller, W. E., & Lefkowitz, R. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402851101 · Cited by 254
Hamid, T., Guo, S. Z., Kingery, J. R., Xiang, X., Dawn, B., & Prabhu, S. D. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq274 · Cited by 252
Duan, S. Z., Ivashchenko, C. Y., Russell, M. W., Milstone, D. S., & Mortensen, R. M. (2005) · Circulation Research · doi:10.1161/01.res.0000179226.34112.6d · Cited by 251
Baeza-Raja, B., & Muñoz-Cánoves, P. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-08-0585 · Cited by 247
“The following expression plasmids were used: pcDNAIII-MKK6(E), pcDNAIII-MKK6(A), Rc actinHA-I B (S32,36A), Rc/CMVHA-p65, pCEVZ9MEKK1, pM-AKT, and pBM6DraA6 (IL-6) (Han et al., 1996; Dickens et al., 1997; Vanden Berghe et al., 1998; Madrid et al., 2001; Purcell et al., 2001) and were generous gifts from Drs.”
BackgroundMethodPrevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors
Xu, D., Li, N., He, Y., Timofeyev, V., Lu, L., Tsai, H.-J., Kim, I.-H., Tuteja, D., Mateo, R. K. P., Singapuri, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609158103 · Cited by 233
Freund, C., Schmidt-Ullrich, R., Baurand, A., Dunger, S., Schneider, W., Loser, P., El-Jamali, A., Dietz, R., Scheidereit, C., & Bergmann, M. W. (2005) · Circulation · doi:10.1161/01.cir.0000164237.58200.5a · Cited by 175
PLANAVILA, A., RODRIGUEZCALVO, R., JOVE, M., MICHALIK, L., WAHLI, W., LAGUNA, J., & VAZQUEZCARRERA, M. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.11.011 · Cited by 173
“Since activation of NF-nB is required for hypertrophic growth of cardiomyocytes [3–6] and MCP-1 transcription”
BackgroundDschietzig, T., Bartsch, C., Richter, C., Laule, M., Baumann, G., & Stangl, K. (2003) · Circulation Research · doi:10.1161/01.res.0000051884.27117.7e · Cited by 169
Interaction Between NFκB and NFAT Coordinates Cardiac Hypertrophy and Pathological Remodeling
Liu, Q., Chen, Y., Auger-Messier, M., & Molkentin, J. D. (2012) · Circulation Research · doi:10.1161/circresaha.111.260729 · Cited by 169
Kanda, T., Saegusa, S., Takahashi, T., Sumino, H., Morimoto, S., Nakahashi, T., Iwai, K., & Matsumoto, M. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.07.181 · Cited by 19
Metadata
- Authors
- Purcell, N. H., Tang, G., Yu, C., Mercurio, F., DiDonato, J. A., & Lin, A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2001-05-29
- Volume
- 98
- Issue
- 12
- Pages
- 6668-6673
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2131577319
- Cited by
- 323
- References
- 57
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.